khalid-radiolabelledaptamers-2019.pdf (556.73 kB)
Radiolabelled aptamers for theranostic treatment of cancer
journal contribution
posted on 2019-03-01, 00:00 authored by Umair Khalid, Chris Vi, Justin Liam Henri, Joanna MacdonaldJoanna Macdonald, Peter EuPeter Eu, Giovanni MandaranoGiovanni Mandarano, Sarah ShigdarSarah ShigdarCancer has a high incidence and mortality rate worldwide, which continues to grow as millions of people are diagnosed annually. Metastatic disease caused by cancer is largely responsible for the mortality rates, thus early detection of metastatic tumours can improve prognosis. However, a large number of patients will also present with micrometastasis tumours which are often missed, as conventional medical imaging modalities are unable to detect micrometastases due to the lack of specificity and sensitivity. Recent advances in radiochemistry and the development of nucleic acid based targeting molecules, have led to the development of novel agents for use in cancer diagnostics. Monoclonal antibodies may also be used, however, they have inherent issues, such as toxicity, cost, unspecified binding and their clinical use can be controversial. Aptamers are a class of single-stranded RNA or DNA ligands with high specificity, binding affinity and selectivity for a target, which makes them promising for molecular biomarker imaging. Aptamers are presented as being a superior choice over antibodies because of high binding affinity and pH stability, amongst other factors. A number of aptamers directed to cancer cell markers (breast, lung, colon, glioblastoma, melanoma) have been radiolabelled and characterised to date. Further work is ongoing to develop these for clinical applications.
History
Journal
PharmaceuticalsVolume
12Issue
1Article number
2Publisher
MDPILocation
Basel, SwitzerlandPublisher DOI
Link to full text
ISSN
1424-8247Language
engPublication classification
C1 Refereed article in a scholarly journalCopyright notice
2018, The AuthorsUsage metrics
Categories
No categories selectedKeywords
EpCAMaptamerscancerchelating agentsdiagnosticsmolecular imagingradiolabeltargeted imagingtheranosticstherapeuticsScience & TechnologyLife Sciences & BiomedicineChemistry, MedicinalPharmacology & PharmacyCELL ADHESION MOLECULENUCLEIC-ACID APTAMERSRADIONUCLIDE THERAPYCLINICAL-APPLICATIONSRADIOLIGAND THERAPYPROSTATE-CANCERCONTRAST AGENTSDNA APTAMERSTUMOR UPTAKEPHASE-II
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC